Substituted pyridines, and use thereof as GSK3 inhibitors
View Patent ↗The invention relates to substituted pyridines and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of haematological disorders, preferably of leukopenia and neutropenia.
1. Compound of the formula
in which
R 1 is a group of the formula
where
* is the attachment site to the heterocycle,
R 6 is pyrid-2-yl, pyrimid-2-yl, 2-aminopyrimid-4-yl, 2-cyclopropylaminopyrimid-4-yl, 2-methylaminopyrimid-4-yl, 2-ethylaminopyrimid-4-yl, 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,2-pyrazol-5-yl,
where pyrid-2-yl, pyrimid-2-yl, 1,3-thiazol-2-yl and 1,3-thiazol-4-yl are substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C- 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl and C 3 -C 6 -cycloalkylcarbonyl,
in which alkyl, alkylamino, alkylcarbonyl, alkylaminocarbonyl and cycloalkylcarbonyl may be substituted by one substituent, where the substituent is selected from the group consisting of halogen, cyano, hydroxyl, amino, trifluoromethyl and C 3 -C 6 -cycloalkyl,
and
where 2-aminopyrimid-4-yl, 2-cyclopropylaminopyrimid-4-yl, 2-methylaminopyrimid-4-yl, 2-ethylaminopyrimid-4-yl and 1,2-pyrazol-5-yl may each be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C- 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl and C 3 -C 6 -cycloalkylcarbonyl,
R 2 is phenyl,
where phenyl may be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consistinf of hydroxyl, halogen, cyano, trifluoromethyl, trifluoromethoxy, aminocarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkoxymethyl, C 1 -C 4 -alkylaminomethyl, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl, C 1 -C 4 -alkylcarbonylamino, C 1 -C 4 -alkylsulphonyl, C 1 -C 4 -alkylsulphonylamino, C 1 -C 4 -alkylaminosulphonyl, phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl and piperazinylmethyl,
in which phenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinylmethyl, piperidinylmethyl, morpholinylmethyl and piperazinylmethyl may each be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of halogen, cyano, trifluoromethyl, trifluoromethoxy and C 1 -C 4 -alkyl,
R 3 is hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 3 -alkyl or cyclopropyl,
either
R 4 is hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 3 -alkyl or cyclopropyl,
and
R 5 is halogen, cyano, trifluoromethyl, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl or 5- or 6-membered heterocyclylcarbonyl,
where heterocyclylcarbonyl may be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
and
where alkylaminocarbonyl may be substituted by one substituent, where the substituent is selected from the group consisting of hydroxyl, amino, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino and 5- or 6-membered heterocyclyl,
in which heterocyclyl may be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
or
R 4 is halogen, cyano, trifluoromethyl, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl or 5- or 6-membered heterocyclylcarbonyl,
where heterocyclylcarbonyl may be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
and
where alkylaminocarbonyl may be substituted by one substituent, where the substituent is selected from the group consisting of hydroxyl, amino, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino and 5- or 6-membered heterocyclyl,
in which heterocyclyl may be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
and
R 5 is hydrogen, halogen, cyano, trifluoromethyl, C 1 -C 3 -alkyl or cyclopropyl,
or one of the salts thereof.
2. The compound according to claim 1 , characterized in that
R 1 is a group of the formula
where
* is the attachment site to the heterocycle,
R 6 is pyrid-2-yl, pyrimid-2-yl, 2-aminopyrimid-4-yl, 2-cyclopropylaminopyrimid-4-yl, 2-methylaminopyrimid-4-yl, 2-ethylaminopyrimid-4-yl, 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,2-pyrazol 5-yl,
where pyrid-2-yl, pyrimid-2-yl, 1,3-thiazol-2-yl and 1,3-thiazol-4-yl are substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C- 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl and C 3 -C 6 -cycloalkylcarbonyl,
in which alkyl, alkylamino, alkylcarbonyl, alkylaminocarbonyl and cycloalkylcarbonyl may be substituted by one substituent, where the substituent is selected from the group consisting of halogen, cyano, hydroxyl, amino, trifluoromethyl and C 3 -C 6 -cycloalkyl,
and
where 2-aminopyrimid-4-yl, 2-cyclopropylaminopyrimid-4-yl, 2-methylaminopyrimid-4-yl, 2-ethylaminopyrimid-4-yl and 1,2-pyrazol-5-yl may each be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of halogen, cyano, nitro, amino, trifluoromethyl, trifluoromethoxy, aminocarbonyl, trifluoromethylcarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C - 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl and C 3 -C 6 -cycloalkylcarbonyl,
R 2 is phenyl,
where phenyl may be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of chlorine, fluorine, trifluoromethyl, trifluoromethoxy, methyl and methoxy,
R 3 is hydrogen,
either
R 4 is hydrogen,
and
R 5 is halogen, cyano, trifluoromethyl, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxycarbonyl, C 1 -C 4 -alkylaminocarbonyl or 5- or 6-membered heterocyclylcarbonyl,
where heterocyclylcarbonyl may be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
and
where alkylaminocarbonyl may be substituted by one substituent, where the substituent is selected from the group consisting of hydroxyl, amino, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino and 5- or 6-membered heterocyclyl,
in which heterocyclyl may be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
or
R 4 is trifluoromethyl,
and
R 5 is cyano,
or one of the salts thereof.
3. The compound according to claim 1 , characterized in that
R 1 is a group of the formula
where
* is the attachment site to the heterocycle,
R 6 is pyrid-2-yl or 1,3-thiazol-2-yl,
where pyrid-2-yl and 1,3-thiazol-2-yl are substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of cyano, nitro, amino, trifluoromethylcarbonyl, ethylcarbonyl and methylcarbonyl,
R 2 is phenyl,
where phenyl is substituted by 1 or 2 substituents, where the substituents are each independently selected from the group consisting of chlorine, fluorine, trifluoromethyl, trifluoromethoxy, methyl and methoxy,
R 3 is hydrogen,
either
R 4 is hydrogen,
and
R 5 is cyano, trifluoromethyl, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, C 1 -C 2 -alkylaminocarbonyl, piperazinylcarbonyl, piperidinylcarbonyl or morpholinylcarbonyl,
where piperazinylcarbonyl, piperidinylcarbonyl and morpholinylcarbonyl may each be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen and C 1 -C 4 -alkyl,
and
where alkylaminocarbonyl may be substituted by one substituent, where the substituent is selected from the group consisting of piperazinyl, piperidinyl and morpholinyl,
where piperazinyl, piperidinyl and morpholinyl may each be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen and C 1 -C 4 -alkyl,
or
R 4 is trifluoromethyl,
and
R 5 is cyano,
or one of the salts thereof.
4. The compound according to claim 1 , characterized in that
R 1 is a group of the formula
where
* is the attachment site to the heterocycle,
R 6 is a group of the formula
where
# is the attachment site to NH,
either
L is cyano,
and
M is hydrogen,
or
L is cyano, nitro or trifluoromethylcarbonyl,
and
M is amino,
R 2 is phenyl,
where phenyl is substituted by 1 or 2 substituents, where the substituents are each independently selected from the group consisting of chlorine, fluorine and methoxy,
R 3 is hydrogen,
either
R 4 is hydrogen,
and
R 5 is cyano, hydroxycarbonyl, methoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, piperazinylcarbonyl or piperidinylcarbonyl,
where piperazinylcarbonyl and piperidinylcarbonyl are each substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of halogen and C 1 -C 4 -alkyl,
and
where methylaminocarbonyl and dimethylaminocarbonyl are substituted by one piperidinyl substituent,
in which piperidinyl is substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of halogen and C 1 -C 4 -alkyl,
or
R 4 is trifluoromethyl,
and
R 5 is cyano,
or one of the salts thereof.
5. A process for preparing the compound of formula (I) or one of the salts thereof, solvates thereof or solvates of the salts thereof according to claim 1 , characterized in that either
[A] a compound of the formula
in which
R 2 , R 3 , R 4 and R 5 are each as defined in claim 1 ,
and
X 1 is halogen, preferably chlorine or fluorine,
is reacted with a compound of the formula
R 1 —H (III)
in which
R 1 is as defined in claim 1
or
[B] a compound of the formula
in which
R 1 , R 2 , R 3 and R 4 are each as defined in claim 1 ,
is reacted with a compound of the formula
R 5a —H (IV)
in which
R 5a is C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino or 5- to 6-membered heterocyclyl,
where heterocyclyl may be substituted by 1 to 3 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
and
where alkylamino may be substituted by one substituent, where the substituent is selected from the group consisting of hydroxyl, amino, hydroxycarbonyl, aminocarbonyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino and 5- or 6-membered heterocyclyl,
in which heterocyclyl may be substituted by 1 to 2 substituents, where the substituents are each independently selected from the group consisting of oxo, halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylamino, C 1 -C 4 -alkylcarbonyl, C 1 -C 4 -alkoxycarbonyl and C 1 -C 4 -alkylaminocarbonyl,
to give a compound of the formula
6. A pharmaceutical composition comprising a compound according to claim 1 in combination with an inert, nontoxic, pharmaceutically suitable excipient.
7. A method of treating a haematological disorder selected from leucopenia and neutropenia in a human or animal comprising administering a therapeutically effective amount of the compound according to claim 1 to the human or animal.
8. A method of ex vivo propagation of adult haematopoietic stem cells from at least one of the group consisting of bone marrow and peripheral blood, or for ex vivo propagation of embryonic stem cells from umbilical cord blood, wherein an effective amount of the compound according to claim 1 is added to increase a rate of proliferation of the haematopoietic stem cells.